We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




H. pylori-Induced Microenvironment of Chronic Inflammation Promotes Cancer Development

By LabMedica International staff writers
Posted on 02 Sep 2008
A recent publication explained how infection with the stomach bacteria Heliobacter pylori promotes the development of gastric cancer.

H. More...
pylori are helical-shaped, Gram-negative bacteria that infect various areas of the stomach and duodenum. While peptic ulcers, gastritis, and duodenitis are caused by H. pylori infection, many who are infected with the organism do not show any symptoms of disease. Helicobacter are the only known microorganisms that can thrive in the highly acidic environment of the stomach. Their helical shape is thought to have evolved to penetrate and favor its motility in the mucus gel layer that lines the stomach.

Chronic gastritis induced by H. pylori is the strongest known risk factor for peptic ulceration and distal gastric cancer, and adherence of the bacteria to gastric epithelial cells is critical for induction of inflammation. The most important known H. pylori strain-specific determinant associated with cancer is the cag pathogenicity island, and cag+ strains augment the risk for severe gastritis and gastric cancer. Using in vitro models of bacterial-gastric epithelial cell interactions, researchers from Vanderbilt University (Nashville, TN, USA) have shown that cag island genes are required for pro-inflammatory cytokine release and induction of apoptosis. Recently, they have used global proteomics approaches to identify additional H. pylori products that are related to pathogenesis within the gastric niche. Extending these results into rodent models (Mongolian gerbils and mice) of H. pylori-induced inflammation and carcinogenesis, they have shown that inactivation of such genes attenuates the development gastric injury and cancer.

In the current study, the investigators concentrated on specific protein factors secreted by cag+ H. pylori. One of these, CagE, was found to induce expression of decay-accelerating factor (DAF), a human gastric epithelial cellular receptor for H. pylori and a mediator of the inflammatory response to this pathogen. H. pylori-induced expression of DAF was dependent upon activation of the p38 mitogen-activated protein kinase pathway but not NF-kappa B (nuclear factor-kappa B).

Since DAF acts to remove nearby immune proteins that can kill cells to prevent unwanted immune damage, increased DAF activity would provide a degree of protection to H. pylori cells in the area. This would allow the bacteria to maintain an environment of persistent inflammation that could reduce the threshold required for more serious diseases--such as gastric cancer--to develop.

Related Links:
Vanderbilt University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.